RABEYA NAZER: Open Payments
NPI 1275255226 · JACKSONVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$558 in 28 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $921 · 2025 $558
Food & beverage: $558
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $136 |
| Novo Nordisk Inc | 5 | $89 |
| Merck Sharp & Dohme LLC | 3 | $59 |
| Lilly USA, LLC | 2 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| PFIZER INC. | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| UCB, Inc. | 1 | $24 |
| Abbott Laboratories | 1 | $22 |
Products named: REPATHA, GARDASIL 9, MOUNJARO, Wegovy, OTEZLA, Ozempic, PREVNAR 20, AIRSUPRA.
Industry payments across FL — which companies pay providers there.
